The emergence of new drug families, particularly immunotherapy, with front runners such as the anti-CD38 mAbs, and soon to come the CAR T cells, TCE/BITEs, etc., the objective of MM being a chronic disease and for some patients with “cure” is close. The gene discussed is CD38; the disease is Miyoshi myopathy.